Privium Fund Management’s ProQR Therapeutics PRQR Stock Holding History

Privium Fund Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	5,520,024 +52,875	+1%	+$87.1K	1.89%	19
2026 Q1	$8.86M	Buy	5,467,149 +109,387	+2%	+$179K	1.84%	17
2025 Q4	$10.8M	Buy	5,357,762 +359,475	+7%	+$840K	1.99%	14
2025 Q3	$10.6M	Buy	4,998,287 +725	+0%	+$1.58K	1.91%	12
2025 Q2	$10M	Buy	4,997,562 +11,929	+0.2%	+$19.4K	2.17%	10
2025 Q1	$6.63M	Hold	4,985,633	–	–	1.73%	13
2024 Q4	$13.2M	Sell	4,985,633 -646,755	-11%	-$2.05M	2.99%	7
2024 Q3	$10.3M	Buy	5,632,388 +51,663	+0.9%	+$97K	2.55%	10
2024 Q2	$9.21M	Buy	5,580,725 +236,279	+4%	+$459K	2.35%	11
2024 Q1	$12.2M	Hold	5,344,446	–	–	3.27%	7
2023 Q4	$11.1M	Hold	5,344,446	–	–	3.1%	8
2023 Q3	$6.95M	Hold	5,344,446	–	–	2.07%	14
2023 Q2	$8.66M	Hold	5,344,446	–	–	2.49%	15
2023 Q1	$11.4M	Hold	5,344,446	–	–	3.82%	6
2022 Q4	$18M	Hold	5,344,446	–	–	6.83%	4
2022 Q3	$4.04M	Hold	5,344,446	–	–	1.47%	22
2022 Q2	$4.16M	Buy	5,344,446 +100,000	+2%	+$74.5K	1.38%	23
2022 Q1	$4.75M	Buy	5,244,446 +478,787	+10%	+$1.6M	1.05%	26
2021 Q4	$38.9M	Buy	+4,765,659	New	+$36.3M	7.72%	2

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Privium Fund Management's PRQR Position: Q2 2026 in Review

Privium Fund Management increased its ProQR Therapeutics (PRQR) stake by 0.97% in Q2 2026, buying an estimated $87.1K and bringing the position to 5,520,024 shares worth $10.3M. The position accounts for 1.89% of the portfolio, ranked #19.

Privium Fund Management first reported a position in PRQR in Q4 2021 and has held it in 19 quarters since. The position peaked at $38.9M in Q4 2021. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Privium Fund Management held 5,520,024 shares of ProQR Therapeutics worth $10.3M as of Q2 2026.
Privium Fund Management bought 52,875 ProQR Therapeutics shares in Q2 2026, an estimated $87.1K.
ProQR Therapeutics made up 1.89% of Privium Fund Management's portfolio in Q2 2026, its #19 holding.
Privium Fund Management first reported a position in ProQR Therapeutics in Q4 2021 and has held it in 19 quarters since.
Privium Fund Management's ProQR Therapeutics position peaked at $38.9M in Q4 2021.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.